Acorda Therapeutics Inc., of Hawthorne, N.Y., added Mark Pinney as chief financial officer.
Actelion Ltd., of Allschwil, Switzerland, appointed Andri Mueller senior vice president, corporate development; Konrad Wirz chief financial officer; Christian Chavy senior vice president, Europe, Canada and Latin America; Simon Buckingham president, United States and Asia/Pacific Region; and Roland Haefeli head of corporate communications.
ActiveCyte Inc., of Newton, Mass., named Richard Gill president and CEO. Gill has been president and CEO of Genome Therapeutics Corp., of Waltham, Mass., and senior vice president and general manager of BTG International Inc., of Philadelphia.
Adolor Corp., of Exton, Pa., appointed David Jackson senior vice president of research and development.
Aptagen Inc., of Herndon, Va., added Jingrong Tang to its scientific staff.
Avant Immunotherapeutics Inc., of Needham, Mass., added Karen Lipton to its board.
Aviron Inc., of Mountain View, Calif., promoted Rayasam Prasad senior vice president, technical affairs.
Biolex Inc., of Pittsboro, N.C., appointed Edward Branson vice president, business development and operations.
Centaur Pharmaceuticals Inc., of Sunnyvale, Calif., added Dushyant Pathak as senior vice president of business development and strategic planning and Philip James as vice president of clinical development. Also, Centaur promoted Kirk Maples to senior vice president of research, John Vajda to senior vice president of operations, and Christine Huh to vice president of human relations.
Coley Pharmaceutical Group, of Wellesley, Mass., and Langenfeld, Germany, added Patricia Dimond as vice president, corporate communications and strategic development. It also named to its scientific advisory board George Demetri, from the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute; Ronald Levy, chief of the division of oncology at Stanford University School of Medicine; Wolfram Sterry, professor and chairman, Department of Dermatology, Chariti University Hospital, Humboldt University in Berlin; and Jerry Weisbach, former president of the Parke Davis Research Division, Warner-Lambert Co.
Commonwealth Biotechnologies Inc., of Richmond, Va., appointed Everette Allen, Donald McAfee and Samuel Sears to its board.
CuraGen Corp., of New Haven, Conn., added Lee Babiss to its scientific advisory board.